

# Prognostic Value of Desaturation during a 6-Minute Walk Test in Idiopathic Interstitial Pneumonia

Vibha N. Lama, Kevin R. Flaherty, Galen B. Toews, Thomas V. Colby, William D. Travis, Qi Long, Susan Murray, Ella A. Kazerooni, Barry H. Gross, Joseph P. Lynch III, and Fernando J. Martinez

Division of Pulmonary and Critical Care Medicine and Department of Radiology, University of Michigan Health System; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan; and the Armed Forces Institute of Pathology, Mayo Clinic, Scottsdale, Arizona

Exercise-induced hypoxia is an index of the severity of interstitial lung disease. We hypothesized that desaturation during a 6-minute walk test would predict mortality for patients with usual interstitial pneumonia ( $n = 83$ ) and nonspecific interstitial pneumonia ( $n = 22$ ). Consecutive patients with biopsy-proven disease performed a 6-minute walk test between January 1996 and December 2001. Desaturation was defined as a fall in oxygen saturation to 88% or less during the 6-minute walk test. Desaturation was common (44 of 83 usual interstitial pneumonia and 8 of 22 nonspecific interstitial pneumonia; chi square,  $p = 0.39$ ). Patients with usual interstitial pneumonia or nonspecific interstitial pneumonia who desaturated had a significantly higher mortality than patients who did not desaturate (respective log-rank tests,  $p = 0.0018$ ,  $p = 0.0089$ ). In patients with usual interstitial pneumonia, the presence of desaturation was associated with an increased hazard of death (hazard ratio, 4.2; 95% confidence interval, 1.40, 12.56;  $p = 0.01$ ) after adjusting for age, sex, smoking, baseline diffusion capacity for carbon monoxide, FVC, and resting saturation. We conclude that knowledge of desaturation during a 6-minute walk test adds prognostic information for patients with usual interstitial pneumonia and nonspecific interstitial pneumonia.

**Keywords:** 6-minute walk test; usual interstitial pneumonia; nonspecific interstitial pneumonia

As a group, patients with usual interstitial pneumonia (UIP) have a poor prognosis (a median survival of 2.8 to 4.0 years) (1–4). The prognosis for any individual patient, however, is variable. As such, additional predictors of survival are important to help patients and physicians stratify the risks and benefits of therapeutic endeavors, including experimental protocols, cytotoxic therapies, and lung transplantation. Recent studies have identified demographic (age, smoking, sex), physiologic (diffusion capacity for carbon monoxide [ $DL_{CO}$ ], FVC, exercise  $Pa_{O_2}$ ), radiographic (amount of fibrosis), and histopathologic features (fibroblastic foci) that are associated with survival (2, 5–11).

A central feature in the pathophysiology of idiopathic pulmonary fibrosis (IPF) is impaired gas exchange that worsens with exercise (1, 12). Exercise-induced widening of alveolar arterial  $O_2$  gradient and a fall in arterial  $PO_2$  are secondary to multiple abnormalities, including ventilation/perfusion mismatching,  $O_2$  diffusion limitation, low mixed venous  $PO_2$ , and right-to-left intracardiac shunting through a patent foramen ovale (13–17).  $Pa_{O_2}$

with exercise (2) and at rest (18) has been shown to predict survival in patients with UIP.

A simple test to evaluate desaturation with exertion is a 6-minute walk test (6MWT) (19, 20). Desaturation of hemoglobin, as measured by pulse oximetry, during a 6MWT is predictive of mortality in patients with primary pulmonary hypertension (21). We hypothesized that desaturation during a 6MWT would provide additional prognostic information regarding survival for patients with UIP and nonspecific interstitial pneumonia (NSIP) after accounting for demographic, physiologic, and radiographic features. Some of the results of this study have been reported in the form of an abstract (22).

## METHODS

### Patient Selection

Consecutive patients with surgical lung biopsy-confirmed UIP and NSIP who underwent a 6MWT on room air between January 1996 and December 2001 formed the study group. This study used patients from the University of Michigan Specialized Center of Research in the Pathobiology of Fibrotic Lung Disease database. The slides were reviewed by two independent pathologists, and the diagnoses of UIP and NSIP were based on American Thoracic Society/European Respiratory Society guidelines (23). Patients with underlying collagen vascular disease or occupational exposure were excluded. A subgroup of these patients has been previously described (7). Approval for the use of these data was obtained from the Institutional Review Board of the University of Michigan.

### Pulmonary Function Testing and High-resolution Computed Tomography

Pulmonary function tests, including spirometry and  $DL_{CO}$ , were performed as previously described (24). High-resolution computed tomography examinations were performed and semiquantitatively scored for ground-glass opacity and interstitial opacity (computed tomography fibrosis score [CT-fib]) as previously described (7, 25). The radiologists were unaware of the histologic diagnosis at the time of interpretation.

### 6MWT

The protocol used for the 6MWT was designed to ensure an accurate assessment of oxygen desaturation and to provide a clinically useful oxygen titration. All patients were tested under standardized conditions in the same pulmonary function laboratory by trained technicians who were blinded to the histologic diagnosis. Baseline blood pressure, heart rate, and oxygen saturation using Nellcore pulse oximetry (Nellcore N-3000; Mallinckrodt Inc., Hazelwood, MO) were measured. If the resting saturation was less than 88% on room air, patients were not considered eligible for room air 6MWT. These patients were excluded from the study group.

Patients were instructed as follows: “The object of this test is to walk as quickly as you can for 6 minutes to cover as much ground as possible. You may slow down if necessary. If you stop we wish you to continue the walk again as soon as possible. Your goal is to walk as fast and as far as you can in 6 minutes.” To ensure an accurate assessment of the oxygen saturation, the respiratory therapist checked that the pulse

(Received in original form February 14, 2003; accepted in final form August 7, 2003)

Supported in part by National Institutes of Health NHLBI Grant #P50HL46487, NHLBI, 1 K24 HL04212, and 1 K23 HL68713.

Correspondence and requests for reprints should be addressed to Fernando J. Martinez, M.D., M.S., 1500 East Medical Center Drive, 3916 Taubman Center, Ann Arbor, MI 48109-0360. E-mail: fmartine@umich.edu

Am J Respir Crit Care Med Vol 168, pp 1084–1090, 2003  
Originally Published in Press as DOI: 10.1164/rccm.200302-2190C on August 13, 2003  
Internet address: www.atsjournals.org

oximeter had an acceptable signal and that the oximeter bar was pulsing to show the heart rate and was in synchrony with the heart rate before beginning all tests. Fingernail polish, if worn by the patient, was removed before testing. Patients walked on a level surface with gentle encouragement using set phrases every 30 seconds.  $\text{Sa}_{\text{O}_2}$  was measured continuously during the walk. If the patient experienced an oxygen saturation of 88% persistent for 1 minute or if saturation fell below 87%, the study was repeated with supplemental oxygen administered using a threshold similar to that of other investigators in this field (26, 27) and following published recommendations (28). Maximal distance was defined as the maximal achieved walk distance during room air or oxygen-supplemented 6MWT.

### Statistical Analysis

Categorical data were compared using chi-square tests (29), and continuous data were compared using two-tailed *t* tests (30). All *t* tests assumed unequal variances with *p* values of less than 0.05 considered statistically significant. Vital status, ascertained as of June 2002, was determined by review of electronic patient charts and review of the most recent social security death index. Survival experiences for desaturation status groups were illustrated via Kaplan-Meier curves (31). Four patients underwent lung transplantation and were censored on the date of transplantation. Cox regression analysis (32) was used to examine the relationship between desaturation and mortality, adjusting for demographic characteristics (age, sex, and smoking status), physiologic data (FVC,  $\text{DL}_{\text{CO}}$ , resting  $\text{Sa}_{\text{O}_2}$ ) and radiographic variables (CT-fib). For the purpose of data analysis, desaturation was defined as fall in  $\text{Sa}_{\text{O}_2}$  equal to or below 88% during the room air 6MWT (27, 28). Additional analyses were performed with decrease in saturation ( $\Delta$  sat = resting saturation – lowest saturation on 6MWT) expressed as a continuous variable or as a 4% decrease from the baseline saturation ( $\Delta$  sat of 4% or more). A logistic regression analysis (33) was used to determine whether baseline demographic, physiologic, radiographic, or histopathologic information could predict desaturation.

### RESULTS

Of the 123 patients who underwent 6MWT during the study period, 18 (UIP = 15, NSIP = 3) were excluded, as their resting saturations were less than 88%, and hence, they did not undergo a room air 6MWT. One hundred and five patients (UIP = 83, NSIP = 22) made up the study group. Table 1 compares the physiologic and walk test characteristics seen in the two cohorts. Thirty-eight UIP and eight NSIP patients met criteria for oxygen supplementation.

A similar proportion of patients with UIP (44 of 83, 53%) and NSIP (8 of 22, 36%) desaturated (chi square, *p* = 0.17). No significant differences were noted in age, sex, smoking history, or treatment given between patients with UIP or NSIP who desaturated versus those that did not desaturate. Similarly, there was no significant difference in the interval between open lung

biopsy and walk test between those who desaturated versus those that did not desaturate (mean biopsy-walk interval: desaturators  $7.84 \pm 18.01$  months [*n* = 52], nondesaturators  $7.67 \pm 16.09$  months [*n* = 53], *p* = 0.95). Patients with UIP who desaturated exhibited significantly lower values of FVC,  $\text{DL}_{\text{CO}}$ , and resting saturation than patients with UIP who did not desaturate. No significant difference in pulmonary function was noted between patients with NSIP who did and did not desaturate, although there was a trend toward a lower  $\text{DL}_{\text{CO}}$  in the group that desaturated. The small number of patients with NSIP may have limited our ability to detect statistically significant differences. Resting saturation was significantly lower in patients with NSIP that desaturated (Table 2).

$\text{DL}_{\text{CO}}$  (odds ratio of 0.50 for a 10-unit increase in  $\text{DL}_{\text{CO}}$  percent predicted; 95% confidence interval [CI], 0.32–0.78; *p* = 0.002) and resting saturation (odds ratio of 0.41 for 1% increase in resting saturation; 95% CI, 0.41–0.87; *p* = 0.0066) were significant predictors of desaturation after adjusting for age, sex, smoking history, CT-fib score, and FVC in patients with UIP. No significant predictors of desaturation were identified in the group with NSIP.

The median follow-up period was 2.93 years (range of 0.1 to 5.7 years) in the UIP group and 3.63 years (0.32 to 5.6 years) in the NSIP group. Patients with UIP or NSIP who desaturated had a significantly higher mortality than patients that did not desaturate (log-rank test, *p* = 0.0018, *p* = 0.0089) (Figures 1 and 2). The 4-year survival rate was higher in the group that did not desaturate on 6MWT (Table 3).

Univariate analysis was performed using variables that have been suggested to influence survival in previous studies of patients with UIP (Table 4). The lack of deaths in the patients with NSIP who did not desaturate precluded further analysis in this subset of patients. The presence of desaturation (hazard ratio [HR], 3.25; 95% CI, 1.47–7.2; *p* = 0.0016), lower FVC (HR for a 1-L increase, 0.65; 95% CI, 0.42–1.00; *p* = 0.05), and lower  $\text{FEV}_1$  (HR for a 1-L increase 0.58; 95% CI, 0.33–0.99; *p* = 0.04) were found to be significant predictors of mortality. Importantly, after adjusting for age, sex, smoking history, baseline  $\text{DL}_{\text{CO}}$  percent predicted, FVC percent predicted, resting saturation, and histologic diagnosis, desaturation on 6MWT remained a significant predictor of mortality in all patients (UIP and NSIP) (HR, 4.47; 95% CI, 1.58–12.64; *p* = 0.005) (Table 5) and when the analysis was repeated only in UIP patients (HR, 4.20; 95% CI, 1.40–12.56; *p* = 0.01) (Table 5). The strength of this association was maintained after adjusting for high-resolution computed tomography fibrotic scores (data not shown).

In additional analyses, we examined alternative approaches to defining a fall in saturation during a 6MWT;  $\Delta$  saturation (resting saturation – lowest saturation on 6MWT as a continuous parameter) was a significant predictor of mortality in both univariate (HR, 1.18; 95% CI, 1.08–1.28; *p* = 0.003) and multivariate analysis (HR, 1.23; 95% CI, 1.08–1.40; *p* = 0.0004). For each percentage decrease in saturation, mortality increased by 23%. As others have suggested that a decrease in saturation of 4% is clinically significant (1, 34), we explored this threshold. A decrease in saturation of 4% or more ( $\Delta$  saturation of four or more) was a significant predictor of mortality in multivariate analysis (HR, 13.58; 95% CI, 1.71–107.54; *p* = 0.01).

### DISCUSSION

In this study, we examined the relationship between desaturation during a 6MWT and survival in patients with UIP and NSIP. We found that desaturation was strongly predictive of mortality. In patients with UIP, after adjusting for age, sex, smoking history, baseline  $\text{DL}_{\text{CO}}$  percent predicted, FVC percent predicted, resting

**TABLE 1. PHYSIOLOGIC AND 6-MINUTE WALK TEST FEATURES OF PATIENTS WITH USUAL INTERSTITIAL PNEUMONIA AND NONSPECIFIC INTERSTITIAL PNEUMONIA**

Characteristic	UIP ( <i>n</i> = 83)	NSIP ( <i>n</i> = 22)	<i>p</i> Value
Resting saturation, %	95.6 ± 1.0	96.0 ± 2.5	0.48*
$\Delta$ Saturation, % points	7.1 ± 4.1	5.7 ± 4.1	0.17*
Desaturation	44 (53%)	8 (36%)	0.17†
$\Delta$ Saturation ≥ 2%	75 (90%)	20 (90%)	0.94†
$\Delta$ Saturation ≥ 4%	66 (80%)	14 (64%)	0.12†
Maximal distance, ft	1,166 ± 355	1,174 ± 313	0.92*

*Definition of abbreviations:* desaturation = oxygen saturation of 88% or less on the 6MWT; NSIP = nonspecific interstitial pneumonia;  $\Delta$  saturation = resting saturation – lowest saturation on 6MWT; UIP = usual interstitial pneumonia.

\* *t* test (unequal variances).

†  $\chi^2$  test.

**TABLE 2. DEMOGRAPHIC, PHYSIOLOGIC, AND HIGH-RESOLUTION COMPUTED TOMOGRAPHY FEATURES OF USUAL INTERSTITIAL PNEUMONIA AND NONSPECIFIC INTERSTITIAL PNEUMONIA**

Variable	Usual Interstitial Pneumonia			Nonspecific Interstitial Pneumonia		
	No Desaturation, n = 39 (mean ± SD)	Desaturation, n = 44 (mean ± SD)	p Value	No Desaturation, n = 14 (mean ± SD)	Desaturation, n = 8 (mean ± SD)	p Value
<b>Demographics</b>						
Age, yr	63 ± 11	61 ± 9	0.29 <sup>†</sup>	57 ± 9	61 ± 10	0.33 <sup>†</sup>
Sex, male/female	20/19	24/20	0.76 <sup>‡</sup>	8/6	6/2	0.40 <sup>‡</sup>
Smokers, %	69	68	0.92 <sup>‡</sup>	64	63	0.93 <sup>‡</sup>
Cigarette consumption, pack years	24 (4–92)*	21.5 (4–80)*	0.54 <sup>†</sup>	33 (7–90)*	36 (14–53)*	0.78 <sup>†</sup>
<b>Treatment</b>						
No treatment	3	1	0.79 <sup>‡</sup>	2	1	0.19 <sup>‡</sup>
Prednisone	6	8		4	3	
Prednisone + azathioprine	16	17		5	0	
Azathioprine	12	14		2	2	
Miscellaneous	2	4		1	2	
<b>Physiologic</b>						
FVC, L	2.60 ± 0.93	2.13 ± 0.61	0.0096 <sup>†</sup>	2.52 ± 0.88	3.09 ± 0.72	0.12 <sup>†</sup>
FVC, % predicted	71 ± 21	58 ± 16	0.0055 <sup>†</sup>	68 ± 23	74 ± 14	0.51 <sup>†</sup>
FEV <sub>1</sub> , L	2.17 ± 0.75	1.80 ± 0.49	0.0089 <sup>†</sup>	1.93 ± 0.66	2.33 ± 0.47	0.11 <sup>†</sup>
FEV <sub>1</sub> , % predicted	83 ± 24	68 ± 17	0.0027 <sup>†</sup>	70 ± 22	79 ± 15	0.31 <sup>†</sup>
DL <sub>CO</sub> ml/min/mm Hg	15.00 ± 5.33	10.42 ± 3.22	< 0.0001 <sup>†</sup>	13.73 ± 4.66	10.98 ± 3.90	0.16 <sup>†</sup>
DL <sub>CO</sub> , % predicted	59 ± 18	42 ± 12	< 0.0001 <sup>†</sup>	57 ± 22	42 ± 13	0.06 <sup>†</sup>
Resting saturation, %	96.31 ± 1.76	94.95 ± 2.03	< 0.0017 <sup>†</sup>	97 ± 1.66	94.3 ± 2.76	0.03 <sup>†</sup>
<b>HRCT</b>						
CT-fib score	1.68 ± 0.55	1.78 ± 0.76	0.50 <sup>†</sup>	1.16 ± 0.82	0.98 ± 0.64	0.64 <sup>†</sup>

*Definition of abbreviations:* CT-fib = semiquantitatively scored interstitial opacity on high-resolution computerized tomography (25); DL<sub>CO</sub> = carbon monoxide diffusion capacity; HRCT = high-resolution computerized tomography; NSIP = nonspecific interstitial pneumonia; UIP = usual interstitial pneumonia.

\* Median (range).

<sup>†</sup> t test (unequal variances).


<sup>‡</sup>  $\chi^2$  test.

Patients are stratified by the presence or absence of desaturation (oxygen saturation OF 88% or less) on a 6-minute walk test.


saturation, and the amount of fibrosis on high-resolution computed tomography, the presence of desaturation was associated with a greater than fourfold hazard of death. Furthermore, all deaths in patients with NSIP occurred in patients who desaturated. We also demonstrate that desaturation is frequently noted in both patients with UIP (44 of 83, 53%) and NSIP (8 of 22, 36%). A significant predictor of desaturation in patients with UIP was DL<sub>CO</sub> after adjusting for age, sex, smoking history,

FVC, and the amount of fibrosis on high-resolution computed tomography.

Our data demonstrate that UIP patients who desaturate during a 6MWT had a more than fourfold higher hazard of dying during follow-up. The prognostic importance of exercise-induced hypoxia has been suggested in the literature (2, 35). In the clinical radiologic physiologic scoring system devised to predict survival in IPF, resting gas exchange was not important; however, exercise Pa<sub>O<sub>2</sub></sub> on cardiopulmonary exercise testing was significantly predictive of survival and accounted for as much as 10.5% of the maximum in predicting survival (2). More recently, in a study of 41 patients with IPF, exercise induced hypoxemia evaluated by  $\Delta Pa_{O_2}/\Delta \dot{V}O_2$  on cardiopulmonary exercise testing was strongly correlated with survival (35). Importantly, other investigators have not confirmed that cardiopulmonary exercise testing measures of gas exchange provide additional prognostic value in IPF patients (24, 36). Furthermore, registry data suggest that exercise testing is infrequently used in clinical practice to evaluate patients with IPF (37). This may relate to the expense and limited availability of this diagnostic modality. In contrast, 6MWT is a simple, inexpensive test that is convenient, requires minimal medical personnel, and can be performed in an office setting (28). Moreover, a good correlation has been demonstrated between O<sub>2</sub> uptake and peak Pa<sub>O<sub>2</sub></sub> between cardiopulmonary exercise testing and 6MWT (38). Furthermore, in a study of 80 consecutive patients with COPD, 6MWT was found to be more sensitive than maximal incremental cycle testing in detecting desaturation defined as fall in saturation of 4% or more by pulse



**Figure 1.** Kaplan-Meier survival curve for patients with usual interstitial pneumonia (UIP) grouped by desaturation (oxygen saturation of 88% or less) on 6MWT (desaturators, dashed line; nondesaturators, solid line; p = 0.0018).



**Figure 2.** Kaplan-Meier survival curve in patients with nonspecific interstitial pneumonia (NSIP) grouped by desaturation (oxygen saturation of 88% or less) on 6MWT (desaturators, dashed line; nondesaturators, solid line;  $p = 0.0089$ ).

oximetry (34). These investigators also confirmed the reproducibility of changes in pulse oximetry on repeat 6MWTs. This is not surprising, as pulse oximetry has been found to be accurate within 2% ( $\pm 1$  SD) or 5% ( $\pm 2$  SD) of *in vitro* oximetry in the range of 70% to 100%  $\text{Sa}_{\text{O}_2}$  (39). Our data demonstrate that desaturation on 6MWT in patients with UIP and NSIP portends a bad prognosis and provides compelling support for the routine use of this technique in patients with UIP and NSIP.

We demonstrate a strong correlation of measures of fall in saturation on a 6MWT and survival independent of the format used to define desaturation. A decrease in saturation below 88% has been used by others examining gas exchange in interstitial disease (27) and to identify patients requiring oxygen supplementation during exercise (28). Importantly, the use of this threshold in our data set provides two equally distributed groups with very different survival rates. The 4-year survival rate of UIP patients who desaturated to this level was 34.5% compared with 69.1% in patients who did not desaturate. The use of a change in saturation as a continuous variable confirms the strong predictive ability of desaturation during 6MWT to predict a less favorable outcome; for each 1% decrease in saturation, mortality increased by 23%. A recent American Thoracic Society consensus statement suggested a 4% decrease in saturation during exercise as an adverse prognostic sign in IPF (1). Our data provide support for this, as patients experiencing such a level of desaturation exhibited a nearly 14-fold increase in mortality, albeit with a wide confidence interval. The latter likely reflects that most patients in the current cohort experienced a decrease in saturation of 4% or more, with only one death noted in the 17 patients who exhibited a decrease in saturation of less than 4%. These data provide a compelling argument for the clinical use of the

**TABLE 3. FOUR-YEAR SURVIVAL RATE FOR PATIENTS WITH NONSPECIFIC INTERSTITIAL PNEUMONIA AND USUAL INTERSTITIAL PNEUMONIA**

	4-Year Survival Rate	95% CI
UIP no desaturation	69.1%	46.2–91.9%
UIP desaturation	34.5%	17.4–51.7%
NSIP no desaturation	100%	—
NSIP desaturation	65.6%	24.7–100%

*Definition of abbreviations:* CI = confidence interval; NSIP = nonspecific interstitial pneumonia; UIP = usual interstitial pneumonia.

Patients are stratified by the presence or absence of desaturation (oxygen saturation of 88% or less) on a 6-minute walk test.

6MWT in the evaluation of patients with UIP and NSIP. As the 4-year survival after lung transplantation in IPF patients is approximately 45% (40), a strong case can be made for referring UIP patients who meet published criteria (41) and who desaturate during 6MWT. As UIP patients who desaturate experience a 4-year survival of 34.5%, they are most likely to experience a survival benefit from lung transplantation. In contrast, UIP patients who do not desaturate during 6MWT experience a 4-year survival of 69.1%, suggesting that a delay in listing may not impair long-term survival in this group.

$\text{DL}_{\text{CO}}$  was a predictor of desaturation on 6MWT in UIP patients but did not correlate with mortality in multivariate models. The prognostic value of the simple 6MWT likely reflects the cumulative impact of ventilation/perfusion mismatching,  $\text{O}_2$  diffusion limitation, low mixed venous  $\text{Po}_2$ , and right-to-left intracardiac shunting through a patent foramen ovale that may be seen in patients with fibrotic lung diseases (13–17). Several authors have suggested a fair correlation between measures of gas exchange during maximal exercise testing and the extent of physiologic or radiologic abnormality in patients with pulmonary fibrosis (42–49). Some have documented modest correlations between static physiologic parameters and desaturation during 6MWT (50) in patients with interstitial lung diseases. Arterial oxygen tension during maximal exercise has been correlated

**TABLE 4. UNIVARIATE ANALYSIS OF SURVIVAL IN PATIENTS WITH USUAL INTERSTITIAL PNEUMONIA**

Parameter	Hazard Ratio (95% CI)	p Value
Demographic age, yr	1.00 (0.97–1.04)	0.81
Male sex	1.05 (0.53–2.08)	0.89
Positive smoking history	0.62 (0.31–1.24)	0.18
Physiology FVC, L	0.65 (0.42–1.00)	0.05
FVC, per 10% predicted	0.84 (0.69–1.00)	0.06
$\text{FEV}_{1\text{r}}$ , L	0.58 (0.33–0.99)	0.04
$\text{FEV}_{1\text{r}}$ , per 10% predicted	0.86 (0.73–1.01)	0.07
$\text{DL}_{\text{CO}}$ ml/min/mm Hg	0.95 (0.87–1.03)	0.21
$\text{DL}_{\text{CO}}$ , per 10% predicted	0.85 (0.68–1.06)	0.13
Timed walk test desaturation	3.25 (1.47–7.20)	0.0016
Resting saturation	0.91 (0.77–1.08)	0.27
Maximal distance, per 10 ft	0.997 (0.989–1.006)	0.53
HRCT CT-fib	1.23 (0.73–2.07)	0.43

*Definition of abbreviations:* CI = confidence interval; CT-fib = semiquantitatively scored interstitial opacity on high-resolution computerized tomography (25); desaturation = oxygen saturation of 88% or less on 6MWT;  $\text{DL}_{\text{CO}}$  = carbon monoxide diffusion capacity; UIP = usual interstitial pneumonia.

TABLE 5. MULTIVARIATE ANALYSIS OF SURVIVAL

Parameter	Hazard Ratio (95% CI)	p Value
All patients		
Age, yr	1.04 (0.99–1.09)	0.09
Male sex	1.18 (0.53–2.63)	0.69
Positive smoking history	0.88 (0.39–1.98)	0.76
DL <sub>CO</sub> , per 10% predicted	1.04 (0.76–1.42)	0.81
FVC, per 10% predicted	0.86 (0.68–1.08)	0.20
UIP	3.14 (0.91–10.92)	0.07
Resting saturation	0.96 (0.79–1.17)	0.67
Desaturation	4.47 (1.58–12.64)	0.005
UIP patients		
Age, yr	1.04 (0.98–1.09)	0.16
Male sex	1.13 (0.49–2.58)	0.78
Positive smoking history	0.79 (0.35–1.83)	0.59
DL <sub>CO</sub> , per 10% predicted	1.11 (0.80–1.55)	0.53
FVC, per 10% predicted	0.85 (0.67–1.07)	0.17
Resting saturation	1.03 (0.82–1.23)	0.97
Desaturation	4.20 (1.40–12.56)	0.01

Definition of abbreviations: CI = confidence interval; desaturation = oxygen saturation of 88% or less on 6MWT; DL<sub>CO</sub> = carbon monoxide diffusion capacity; UIP = usual interstitial pneumonia.

with DL<sub>CO</sub> in patients with IPF (51–53). Given the prognostic value of exercise desaturation in patients with primary pulmonary hypertension (21), it may be that the additional value afforded by a measurement of exercise induced desaturation in UIP and NSIP reflects the contribution of pulmonary hypertension that is frequently noted in fibrotic lung disease (54). The simplicity of the 6MWT and its probable ability to assess complex physiologic interactions and predict prognosis make the 6MWT an important tool for the management of patients with IPF.

Another novel finding of this study is the documentation that a fall in saturation during 6MWT is a very common phenomenon in patients with UIP and NSIP. Ninety percent of the patients with UIP and NSIP had a fall in saturation of 2% or more, and desaturation to 88% or less was seen in approximately 50% and 36% of patients with UIP and NSIP, respectively. Gas exchange during exercise has been suggested as an important pathophysiologic abnormality in patients with idiopathic interstitial pneumonia (1, 12). Although most of the studies evaluating exercise-induced desaturation have used cardiopulmonary exercise testing, two recent studies have examined saturation during a 6MWT in patients with interstitial lung disease. Desaturation to 88% or less was seen in 38% of patients with interstitial lung diseases (33 of 50 with IPF) on a 6MWT (27). Similarly, in a study of 40 patients with varying interstitial lung diseases (19 IPF patients), eight patients exhibited a drop of 2–5%, whereas 16 experienced desaturation of more than 5% on a 6MWT (50). Importantly, our study examines a large number of patients with specific histologic diagnoses and confirms that desaturation on a 6MWT is a common finding in patients with UIP and NSIP.

Another interesting finding of our study was that no difference was seen in the frequency and degree of fall in saturation during a 6MWT in patients with UIP and NSIP. Some investigators have suggested a greater rise in the alveolar arterial O<sub>2</sub> during exercise in patients with UIP compared with desquamative interstitial pneumonia, asbestosis, berylliosis, sarcoidosis, or  $\alpha$ -1 antitrypsin-related emphysema (53, 55). In contrast, the trough saturation was similar in a retrospective series of patients with NSIP (n = 14) compared with UIP (n = 63); the mode of exercise testing or proportion with desaturation was not described (3). In our study, we found no statistical difference in any of the variables obtained during a 6MWT, including resting saturation, various degrees of fall in saturation, and maximal

distance walked in patients with NSIP and UIP. Together, these studies suggest that desaturation on 6MWT in patients with UIP and NSIP is seen more frequently than other pulmonary diseases and occurs with similar frequency in patients with UIP and NSIP.

In conclusion, desaturation during a 6MWT is a strong predictor of mortality in patients with UIP and NSIP. This effect persists after adjustment for patient demographic factors, static physiologic testing, and the amount of fibrosis on high-resolution computed tomography. This simple exercise modality, which can be easily obtained in an outpatient setting at a low cost, may be particularly important in prognostication in patients with UIP and NSIP and may help optimize referral and listing of patients for lung transplantation. Our data also suggest that desaturation on a 6MWT could be used for stratification of patients with UIP in clinical trials, as these two groups exhibit a very different survival profile. Further research is required to determine the role of serial measures of 6MWT in the follow-up of patients with UIP and whether desaturation on a 6MWT can be used as a surrogate for survival in phase II trials. Although 6MWT has been suggested as a measure of functional capacity with distance as the primary endpoint, our data confirm that documentation of desaturation offers important information in patients with UIP and NSIP.

**Conflict of Interest Statement:** V.N.L. has no declared conflict of interest; K.R.F. has no declared conflict of interest; G.B.T. has no declared conflict of interest; T.V.C. has no declared conflict of interest; W.D.T. has no declared conflict of interest; Q.L. has no declared conflict of interest; S.M. has no declared conflict of interest; E.A.K. received research funding from GE Medical Systems, CT Division, in 2003 totaling \$40,000, serves on the GE Medical Advisory Board for CT, serves on the Board of the GE Radiology Research Academic Fellowship (and receives \$2,500 annually), and received \$1,500 for a lecture by GE in 2002; B.H.G. has no declared conflict of interest; J.P.L. has no declared conflict of interest; F.J.M. has no declared conflict of interest.

**Acknowledgment:** The University of Michigan Fibrotic Lung Disease Network includes the following: D. Arenberg, W. Bria, D. Dahlgren, S. Gay, C. Grum, J. Hampton, T. Ojo, M. Peters-Golden, R. Simon, T. Sisson, T. Standiford, R. Hyzy (University of Michigan, Division of Pulmonary and Critical Care, Ann Arbor, MI); P. Bachwich, C. Easton, J. Mazur (Internal Medicine Clinic, Alpena, MI); S. Chaparala, G. Harrington, N. Potempa (The Lung Center, Battle Creek, MI); S. Manawar, J. Summer (Bay City, MI); P. Hukku, J. Sung (Clawson, MI); R. Babcock (Clinton Township, MI); J. Belen, M. Dunn, D. Maxwell, R. Reagle, R. Sherman, S. Simecek (Pulmonary and Critical Care Medicine Consultants, Commerce, MI); L. Victor (Oakwood Hospital, Dearborn, MI); B. DiGiovine, M. Eichenhorn, J. Popovich, Jr., D. Spizarny (Henry Ford Hospital, Detroit, MI); B. Rabinowitz (Botsford General Hospital, Farmington Hills, MI); G. Ferguson, P. Kaplan, S. Sklar, W. VanderRoest (Pulmonary and Critical Care Specialists, Farmington Hills, MI); O. Filos, V. Rao, M.V. Thomas, J. Varghese, J. Vyskocil, F. Wadenstorer (Pulmonary Associates, PC, Flint, MI); J. Cantor, W. Katz, R. Johnson, Jr., D. Listello, J. Wilt (Grand Valley Internal Medicine, Grand Rapids, MI); C. Acharya, W. Couwenhoven, T. Daum, M. Harrison, M. Koets, G. Sandman, G. VanOtteren (Michigan Medical Professional Company, Grand Rapids, MI); S. Kraker (Michigan Medical, PC, Holland, MI); M. Greenberger, A. O'Neill, D. Wu (Huntington Woods, MI); R.C. Albertson, III, J. Chauncey, T. Murray, G. Patten (Pulmonary Clinics of Southern Michigan, Jackson, MI); T. Abraham, J. Dirks, B. Dykstra, G. Grambau, J. Schoell (Associated Pulmonary and Critical Care Specialists, PC, Kalamazoo, MI); R. Brush, S. Jefferson, J. Miller, S. Schuldheisz, M. Warlick (Pulmonary and Critical Care Associates, PC, Kalamazoo, MI); J. Armstrong, A. Atkinson, T. Kantra, L. Rawsthorne, D. Young (Pulmonary and Critical Care Consultants, Lansing, MI); A. Abbasi, C.M. Gera, G. Kashyap, J. Morlock (Pulmonary Services, Lansing, MI); S. Danek, A. Saari (Respiratory Medicine, Marquette, MI); S. Yadam (Midland, MI); E. Obeid (Central Michigan Healthcare System, Mt. Pleasant, MI); D. Hoch, A. Kleaveland (Muskegon Pulmonary Associates, Muskegon, MI); A. Allam, M.A. Gad, Jr. (Owosso Medical Group, Owosso, MI); A. Desai, U. Dhanjal, A. Sethi (Lung Associates, Pontiac, MI); F. Ahmad, R. Elkus, L. Kaiser, L. Rosenthal, D. Sak (St. Joseph's Hospital, Pontiac, MI); R. Ailani, M. Basha, A. Hadar, S. Holstine (Physician Health-Care Network, Port Huron, MI); M.W. Al-Ameri, R. Go, M. Kashlan (Pulmonary, Critical Care, and Sleep, PC, Rochester Hills, MI); K. Aggarwal (Rochester, MI); W. Hanna, R. Marchese (Roseville, MI); R. Begle, D. Erb, K.P. Ravikrishnan, J. Seidman, S. Sherman (William Beaumont Hospital, Royal Oak, MI); M. Ivey (Spring Lake, MI); S. Deskins, A. Palmer, S. Shastri (Lakeside Healthcare Specialists, St. Joseph, MI); R. DiLisio, S. Galens, K. Grady, D. Harrington, R. Herbert, C. Hughes, J. Lee, A. Starrico, K. Stevens, M. Trunsky, W. Ventimiglia (Pulmonary and Critical Care Associates, St. Clair Shores, MI and Troy, MI); D. Mahajan (Taylor, MI); H. Kaplan, L. Tankanow (Pulmonary Medicine Associates, Warren, MI); M. Pensler (Henry Ford Wyandotte Hospital, Wyandotte, MI); F.O. Horton, III, A. Nathanson, and R. Wainz (Toledo Pulmonary and Sleep Specialists, Toledo, OH).

## References

- American Thoracic Society: idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement: American Thoracic Society (ATS), and the European Respiratory Society (ERS). *Am J Respir Crit Care Med* 2000;161:646–664.
- King TE Jr, Tooze JA, Schwarz MI, Brown K, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. *Am J Respir Crit Care Med* 2001;164:1171–1181.
- Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 1998;157:199–203.
- Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH, Jain A, Strawderman RL, Flint A, Lynch JP, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. *Am J Respir Crit Care Med* 2001;164:1722–1727.
- Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2002;166:173–177.
- King TE Jr, Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA Jr, Flint A, Thurlbeck W, Cherniack RM. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. *Am J Respir Crit Care Med* 2001;164:1025–1032.
- Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH, Jain A, Strawderman RL, Paine R, Flint A, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. *Eur Respir J* 2002;19:275–283.
- Mogulkoc N, Brutsche MH, Bishop PW, Greaves SM, Horrocks AW, Egan JJ. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. *Am J Respir Crit Care Med* 2001;164:103–108.
- Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis. Impact of oxygen and colchicine, prednisone, or no therapy on survival. *Am J Respir Crit Care Med* 2000;161:1172–1178.
- Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. *Am J Respir Crit Care Med* 2000;162:2213–2217.
- Flaherty KR, Colby TV, Travis WD, Toews GB, Mumford S, Murray S, Thannickal VJ, Kazerooni EA, Gross BH, Lynch JP III, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. *Am J Respir Crit Care Med* 2003;167:1410–1415.
- Agusti AG, Roca J, Rodriguez-Roisin R, Xaubet A, Agustí-Vidal A. Different patterns of gas exchange response to exercise in asbestosis and idiopathic pulmonary fibrosis. *Eur Respir J* 1988;1:510–516.
- O'Donnell DE. Physiology of interstitial lung disease. In: Schwarz M, King T Jr, editors. *Interstitial Lung Disease*. Hamilton, ON: B.C. Decker; 1998. p. 51–70.
- Jernudd-Wilhelmsson Y, Hornblad Y, Hedenstierna G. Ventilation-perfusion relationships in interstitial lung disease. *Eur J Respir Dis* 1986;68:39–49.
- Wagner PD. Ventilation-perfusion matching during exercise. *Chest* 1992;101:192S–198S.
- Hansen JE, Wasserman K. Pathophysiology of activity limitation in patients with interstitial lung disease. *Chest* 1996;109:1566–1576.
- Wasserman K, Hansen JE, Sue DY, Whipp BJ, Casaburi R. Principles of exercise testing and interpretation: including pathophysiology and clinical applications, 3rd ed Vol. 15. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 556.
- Timmer SJ, Karamzadeh AM, Yung GL, Kriett J, Jamieson SW, Smith CM. Predicting survival of lung transplantation candidates with idiopathic interstitial pneumonia: does Pa<sub>O</sub><sub>2</sub> predict survival? *Chest* 2002;122:779–784.
- Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. *Chest* 2001;119:256–270.
- Steele B. Timed walk tests of exercise capacity in chronic cardiopulmonary illness. *J Cardiopulm Rehabil* 1996;16:25–33.
- Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. *Eur Respir J* 2001;17:647–652.
- Lama VN, Flaherty KR, Colby TV, Travis WD, Toews GB, Lynch JP III, Kazerooni EA, Gross BH, Murray S, Mumford JA, et al. Exercise induced desaturation and mortality in usual interstitial pneumonia (UIP). *Am J Respir Crit Care Med* 2003;167:A300.
- American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. *Am J Respir Crit Care Med* 2002;165:277–304.
- Gay SE, Kazerooni EA, Toews GB, Lynch JP III, Gross BH, Cascade PN, Spizarny DL, Flint A, Schork MA, Whyte RI, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. *Am J Respir Crit Care Med* 1998;157:1063–1072.
- Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, Cascade PN, Whyte RI, Lynch JP III, Toews G. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. *AJR Am J Roentgenol* 1997;169:977–983.
- Stevens D, Elperin E, Sharma K, Szidon P, Ankin M, Kesten S. Comparison of hallway and treadmill six-minute walk tests. *Am J Respir Crit Care Med* 1999;160:1540–1543.
- Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related quality of life in patients with interstitial lung disease. *Chest* 1999;116:1175–1182.
- American Association for Respiratory Care: AARC clinical practice guideline: exercise testing for evaluation of hypoxemia and/or desaturation. *Respir Care* 2001;46:514–522.
- Pearson K. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. *Philosophical Magazine* 1900; Series 5, 50:157–175.
- Gosset WS. The probable error of a mean. *Biometrika* 1908;6:1–25.
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 1958;53:457–481.
- Cox DR. Regression models and life tables (with discussion). *J R Stat Soc* 1972;B34:187–220.
- Aldrich JH, Nelson FD. Linear probability, logit and probit models. Newbury Park, CA: Sage; 1984.
- Poulain M, Durand F, Palomba B, Ceugniet F, Desplan J, Varray A, Prefaut C. 6-Minute walk testing is more sensitive than maximal incremental cycle testing for detecting oxygen desaturation in patients with COPD. *Chest* 2003;123:1401–1407.
- Miki K, Maekura R, Hiraga T, Okuda Y, Okamoto T, Hirotsu A, Ogura T. Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis. *Respir Med* 2003;97:482–490.
- Erbes R, Schaberg T, Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis: are they helpful for predicting outcome? *Chest* 1997;111:51–57.
- Mapel DW, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis: past, present, and future. *Chest* 1996;110:1058–1067.
- Troosters T, Vilaro J, Rabinovich R, Casas A, Barbera JA, Rodriguez-Roisin R, Roca J. Physiological responses to the 6-min walk test in patients with chronic obstructive pulmonary disease. *Eur Respir J* 2002;20:564–569.
- Jensen LA, Onyskiw JE, Prasad NG. Meta-analysis of arterial oxygen saturation monitoring by pulse oximetry in adults. *Heart Lung* 1998;27:387–408.
- Hertz MI, Taylor DO, Trulock EP, Boucek MM, Mohacs PJ, Edwards LB, Keck BM. The registry of the international society for heart and lung transplantation: nineteenth official report-2002. *J Heart Lung Transplant* 2002;21:950–970.
- American Society for Transplant Physicians/American Thoracic Society/European Respiratory Society/International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates. *Am J Respir Crit Care Med* 1998;158:335–339.
- Gaensler EA, Carrington CB, Coutu RE, Fitzgerald MX. Radiographic-physiologic-pathologic correlations in interstitial pneumonias. In: Basset F, Georges R, eds. *Progress in Respiration Research Vol. 8: Alveolar interstitium of the lung*. New York: Karger, 1975;223–241.
- Crystal RG, Fulmer JD, Roberts WC, Moss ML, Line BR, Reynolds HY. Idiopathic pulmonary fibrosis: clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. *Ann Intern Med* 1976;85:769–788.
- Fulmer JD, Roberts WC, Crystal RG. Diffuse fibrotic lung disease: a correlative study. *Chest* 1976;69:263–265.
- Chinet T, Jaubert F, Dusser D, Danel C, Chretien J, Huchon GJ. Effects of inflammation and fibrosis on pulmonary function in diffuse lung fibrosis. *Thorax* 1990;45:675–678.

46. Cherniack RM, Colby TV, Flint A, Thurlbeck WM, Waldron JA Jr, Ackerson L, Schwarz MI, King TE Jr. Correlation of structure and function in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 1995;151:1180-1188.
47. Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. *Am Rev Respir Dis* 1986;133:97-103.
48. Wells AU, King AD, Rubens MB, Cramer D, du Bois RM, Hansell DM. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. *Am J Respir Crit Care Med* 1997;155:1367-1375.
49. Xaubet A, Agusti C, Luburich P, Roca J, Monton C, Ayuso MC, Barbera JA, Rodriguez-Roisin R. Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 1998;158:431-436.
50. Chetta A, Aiello M, Foresi A, Marangio E, D'Ippolito R, Castagnaro A, Olivieri D. Relationship between outcome measures of six-minute walk test and baseline lung function in patients with interstitial lung disease. *Sarcoidosis Vasc Diffuse Lung Dis* 2001;18:170-175.
51. Agusti C, Xaubet A, Agusti AGN, Roca J, Ramirez J, Rodriguez-Roisin R. Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 year follow-up. *Eur Respir J* 1994;7:643-650.
52. Andersen SJ, Arvidsson U, Fransson L, Nemcek K, Svensson SE. The relationship between the transfer factor obtained at rest, and arterial oxygen tension during exercise, in patients with miscellaneous pulmonary diseases. *J Intern Med* 1992;232:415-419.
53. Risk C, Epler GR, Gaensler EA. Exercise alveolar-arterial oxygen pressure difference in interstitial lung disease. *Chest* 1984;85:69-74.
54. Arcasoy SM, Christie JD, Ferrari VA, Sutton MSJ, Zisman DA, Blumenthal NP, Pochettino A, Kotloff RM. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. *Am J Respir Crit Care Med* 2003;167:735-740.
55. Keogh BA, Lakatos E, Price D, Crystal RG. Importance of the lower respiratory tract in oxygen transfer: exercise testing in patients with interstitial and destructive lung diseases. *Am Rev Respir Dis* 1984;129:S76-S80.